Vitamin B3
Test Summary
Nicotinic acid occurs naturally in plants and animals and is also added to many foods as a vitamin supplement.
Aliases
- N/A
Specimen Collection
Special Instructions
N/A
Preferred Specimen
2 mL frozen serum collected in a red-top tube (no gel)
Minimum Volume
0.5 mL
Instructions
See Vitamin Collection Link
Patient Preparation
N/A
Storage
N/A
Transport Temperature
Frozen
Specimen Stability
- Room temperature: Unacceptable
- Refrigerated: Unacceptable
- Frozen: 30 days
Limitations
N/A
Other Acceptable Specimens
Frozen plasma collected in a light protected EDTA (lavender-top) tube
Unacceptable Specimens
Serum separator tubes
Order Code
VTMB3
EPIC (Premier) Code
LAB5502
Includes
Nicotinamide and Nicotinic Acid
CPT Code
- 84591
Billing Code
- 670796
CPT Statement
Methodology
Chromatography/Mass Spectrometry
FDA Status
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Physician Attestation of Informed Consent
N/A
Testing Laboratory
Quest Diagnostics Nichols Institute Valencia
27027 Tourney Road
Valencia CA, 91355
27027 Tourney Road
Valencia CA, 91355
Department
Reference Testing
Reference Range
Nicotinamide
Nicotinamide is a metabolite of nicotinic acid. Due to the large variability in the metabolism of nicotinic acid, plasma concentrations of this metabolite are variable. In one study, fasting plasma concentrations were reported to be approximately 40 ng/mL. In another study it was reported that the administration of a single 1000 mg of extended-release tablet of nicotinic acid resulted in a mean peak nicotinamide concentration of 400 ng/mL between 5 and 10 hours post dose, decreasing to about 100 ng/mL by 16 hours post dose.
Nicotinic Acid
Due to the large variability in the metabolism of nicotinic acid, the dosing preparation used (immediate-release vs. extended release), and the mg doses used, the serum concentrations may range from less than 20 ng/mL to about 30,000 ng/mL. After oral administration of an immediate-release tablet, peak plasma concentrations occur in 4 to 5 hours. The plasma half-life of nicotinic acid is about one hour. In one study, fasting plasma concentrations were reported to be less than 20 ng/mL. In another study, it was reported that the administration of a single 1000 mg extended-release tablet resulted in mean nicotinic acid concentrations of less than 50 ng/mL.
Nicotinamide is a metabolite of nicotinic acid. Due to the large variability in the metabolism of nicotinic acid, plasma concentrations of this metabolite are variable. In one study, fasting plasma concentrations were reported to be approximately 40 ng/mL. In another study it was reported that the administration of a single 1000 mg of extended-release tablet of nicotinic acid resulted in a mean peak nicotinamide concentration of 400 ng/mL between 5 and 10 hours post dose, decreasing to about 100 ng/mL by 16 hours post dose.
Nicotinic Acid
Due to the large variability in the metabolism of nicotinic acid, the dosing preparation used (immediate-release vs. extended release), and the mg doses used, the serum concentrations may range from less than 20 ng/mL to about 30,000 ng/mL. After oral administration of an immediate-release tablet, peak plasma concentrations occur in 4 to 5 hours. The plasma half-life of nicotinic acid is about one hour. In one study, fasting plasma concentrations were reported to be less than 20 ng/mL. In another study, it was reported that the administration of a single 1000 mg extended-release tablet resulted in mean nicotinic acid concentrations of less than 50 ng/mL.
Setup Schedule / Expected Turnaround Time
Tuesday, Thursday, Saturday; Report available: 2 - 4 days
Resources
Specimen Collection
Special Instructions
N/A
Preferred Specimen
2 mL frozen serum collected in a red-top tube (no gel)
Minimum Volume
0.5 mL
Instructions
See Vitamin Collection Link
Patient Preparation
N/A
Storage
N/A
Transport Temperature
Frozen
Specimen Stability
- Room temperature: Unacceptable
- Refrigerated: Unacceptable
- Frozen: 30 days
Limitations
N/A
Other Acceptable Specimens
Frozen plasma collected in a light protected EDTA (lavender-top) tube
Unacceptable Specimens
Serum separator tubes
Result Information
Methodology
Chromatography/Mass Spectrometry
Testing Laboratory
N/A
Reference Range
Nicotinamide
Nicotinamide is a metabolite of nicotinic acid. Due to the large variability in the metabolism of nicotinic acid, plasma concentrations of this metabolite are variable. In one study, fasting plasma concentrations were reported to be approximately 40 ng/mL. In another study it was reported that the administration of a single 1000 mg of extended-release tablet of nicotinic acid resulted in a mean peak nicotinamide concentration of 400 ng/mL between 5 and 10 hours post dose, decreasing to about 100 ng/mL by 16 hours post dose.
Nicotinic Acid
Due to the large variability in the metabolism of nicotinic acid, the dosing preparation used (immediate-release vs. extended release), and the mg doses used, the serum concentrations may range from less than 20 ng/mL to about 30,000 ng/mL. After oral administration of an immediate-release tablet, peak plasma concentrations occur in 4 to 5 hours. The plasma half-life of nicotinic acid is about one hour. In one study, fasting plasma concentrations were reported to be less than 20 ng/mL. In another study, it was reported that the administration of a single 1000 mg extended-release tablet resulted in mean nicotinic acid concentrations of less than 50 ng/mL.
Nicotinamide is a metabolite of nicotinic acid. Due to the large variability in the metabolism of nicotinic acid, plasma concentrations of this metabolite are variable. In one study, fasting plasma concentrations were reported to be approximately 40 ng/mL. In another study it was reported that the administration of a single 1000 mg of extended-release tablet of nicotinic acid resulted in a mean peak nicotinamide concentration of 400 ng/mL between 5 and 10 hours post dose, decreasing to about 100 ng/mL by 16 hours post dose.
Nicotinic Acid
Due to the large variability in the metabolism of nicotinic acid, the dosing preparation used (immediate-release vs. extended release), and the mg doses used, the serum concentrations may range from less than 20 ng/mL to about 30,000 ng/mL. After oral administration of an immediate-release tablet, peak plasma concentrations occur in 4 to 5 hours. The plasma half-life of nicotinic acid is about one hour. In one study, fasting plasma concentrations were reported to be less than 20 ng/mL. In another study, it was reported that the administration of a single 1000 mg extended-release tablet resulted in mean nicotinic acid concentrations of less than 50 ng/mL.
Setup Schedule / Expected Turnaround Time
Tuesday, Thursday, Saturday; Report available: 2 - 4 days